These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27565932)

  • 1. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.
    Ono A; Murakami H; Serizawa M; Wakuda K; Kenmotsu H; Naito T; Taira T; Koh Y; Ohde Y; Nakajima T; Endo M; Takahashi T
    Lung Cancer; 2016 Sep; 99():151-4. PubMed ID: 27565932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
    Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
    Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
    Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
    J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate.
    Owusu-Brackett N; Johnson R; Schindel DT; Koduru P; Cope-Yokoyama S
    Cancer Genet; 2013; 206(9-10):353-6. PubMed ID: 24290361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report.
    Liu Q; Wei J; Liu X; Wang J
    Medicine (Baltimore); 2019 Dec; 98(52):e18414. PubMed ID: 31876714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
    Mikes RE; Jordan F; Hutarew G; Studnicka M
    Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-positive gastric inflammatory myofibroblastic tumor in an adult with familial adenomatous polyposis and diffuse fundic polyposis.
    Fan J; Huang B; Yang X; Yang M; He J; Nie X
    Diagn Pathol; 2017 Sep; 12(1):68. PubMed ID: 28923119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.
    Li J; Yin WH; Takeuchi K; Guan H; Huang YH; Chan JK
    Diagn Pathol; 2013 Sep; 8():147. PubMed ID: 24034896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
    Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
    J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
    J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.